Anti-VEGF

Description

The development of therapy with anti-angiogenics or vascular endothelial growth factor inhibitors (anti-VEGF) has marked the beginning of a new era in neovascularization and macular edema treatment. Its main goals are the inhibition of growth and development of new vessels along with the reduction of vascular permeability. The advantages over conventional laser photocoagulation are evident as laser treatment always leaves scars and causes a retinal sensitivity deterioration.Starting with an outline of treatment principles, this volume covers all aspects of anti-VEGF therapy for ophthalmological disorders. In particular, specific chapters are dedicated to age-related macular degeneration, degenerative myopia, angioid streaks, inflammatory diseases, hereditary dystrophies, retinal vein occlusion, diabetic retinopathy, ocular tumors, as well as anterior segment neovascularization.The book gives an update on the application of anti-VEGF in ocular diseases to general ophthalmologists as well as retina specialists.

Informations

• Publié par: S. Karger AG
• Date de parution: 13 août 2010
• Nombre de lectures: 0
• EAN13: 9783805595308
• Langue: English
• Poids de l'ouvrage: 1 Mo

Extrait

Anti-VEGF
Developments in Ophthalmology
Vol. 46
Series Editors
F. Bandello     Milan
W. Behrens-Baumann     Magdeburg
 
Anti-VEGF
Volume Editors
F. Bandello     Milan
M. Battaglia Parodi     Milan
Co-Editors
A.J. Augustin     Karlsruhe
P. Iacono     Rome
R.O. Schlingemann     Amsterdam
U. Schmidt-Erfurth     Vienna
F.D. Verbraak     Amsterdam
12 figures, 5 in color, and 13 tables, 2010
_________________________
__________________________
Francesco Bandello Department of Ophthalmology University Vita-Salute Scientific Institute San Raffaele ViaOlgettina,60 IT-20132 Milano (Italy)
Maurizio Battaglia Parodi Department of Ophthalmology University Vita-Salute Scientific Institute San Raffaele Via Olgettina,60 IT-20132 Milano (Italy)
Library of Congress Cataloging-in-Publication Data
Anti-VEGF / volume editors, Francesco Bandello, M. Battaglia Parodi; co-editors, A. Augustin ... [et al.].
p.;cm. –– (Developments in ophthalmology, ISSN 0250-3751 ;v.46)
Includes bibliographical references and indexes.
ISBN 978-3-8055-9529-2 (hard cover: alk. paper) –– ISBN 978-3-8055-9530-8 (e-ISBN)
I. Eye-Blood-vessels-Diseases-Chemotherapy. 2. Vascular endothelial growth factors-Antagonists-Therapeutic use. I. Bandello, F. (Francesco)
II. Battaglia Parodi, M. (Maurizio) III. Series: Developments in ophthalmology; v. 46.0250-3751
[DNLM:1. Eye Diseases-therapy. 2. Vascular Endothelial Growth Factors-therapeutic use. 3. Neovascularization, Pathologic-therapy. W1 DE998NG v.46 2010 /WW 166 A6334 2010]
RE720.A58 2010
617.7'061-dc22
2010025184
Bibliographic Indices. This publication is listed in bibliographic services, including Current Contents® and Index Medicus.
Disclaimer. The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the book is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Drug Dosage. The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
© Copyright 2010 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)
www.karger.com
Printed in Switzerland on acid-free and non-aging paper (ISO 9706) by Reinhardt Druck, Basel
ISSN 0250–3751
ISBN 978–3–8055–9529–2
e-ISBN 978–3–8055–9530–8
 
Contents
List of Contributors
Preface
Bandello, F. (Milan)
Angiostatic and Angiogenic Factors
de Groot, H.; Schmit-Eilenberger, V.; Kirchhof, J.; Augustin, A.J. (Karlsruhe)
Mechanisms of Ocular Angiogenesis and Its Molecular Mediators
Siemerink, M.J. (Amsterdam); Augustin, A.J. (Karlsruhe); Schlingemann, R.O. (Amsterdam)
Antivascular Endothelial Growth Factors in Age-Related Macular Degeneration
Schmidt-Erfurth, U.; Pollreisz, A.; Mitsch, C.; Bolz, M. (Vienna)
Antivascular Endothelial Growth Factor in Diabetic Retinopathy
Iacono, P. (Rome); Battaglia Parodi, M.; Bandello, F. (Milan)
Retinal Vein Occlusions
Buehl, W.; Sacu, S.; Schmidt-Erfurth, U. (Vienna)
Antivascular Endothelial Growth Factor for Choroidal Neovascularization in Pathologic Myopia
Battaglia Parodi, M. (Milan); Iacono, P. (Rome); Bandello, F. (Milan)
Antivascular Endothelial Growth Factors for Inflammatory Chorioretinal Disorders
Battaglia Parodi, M. (Milan); Iacono, P. (Rome); Verbraak, F.D. (Amsterdam); Bandello, F. (Milan)
Antivascular Endothelial Growth Factor Treatment in Pseudoxanthoma Elasticum Patients
Verbraak, FD. (Amsterdam)
Antivascular Endothelial Growth Factor in Hereditary Dystrophies
Battaglia Parodi, M. (Milan); Iacono, P. (Rome); Bandello, F. (Milan)
Antivascular Endothelial Growth Factor as an Approach for Macular Edema
Buchholz, P.M.; Buchholz, A.P.; Augustin, A.J. (Karlsruhe)
Angiogenesis and Vascular Endothelial Growth Factors in Intraocular Tumors
Missotten, G.S. (Leuven/Amsterdam); Schlingemann, R.O. (Amsterdam);
Jager, M.J. (Leiden)
Antivascular Endothelial Growth Factors in Anterior Segment Diseases
Scholl, S.; Kirchhof, J.; Augustin, A.J. (Karlsruhe)
Author Index
Subject Index
 
List of Contributors
A.J. Augustin, Prof. Augenklinik Moltkestrasse 90 DE-76133 Karlsruhe (Germany) E-Mail [e-mail]
F. Bandello, Prof. Department of Ophthalmology University Vita-Salute Scientific Institute San Raffaele Via Olgettina, 60 IT-20132 Milano (Italy) E-Mail [e-mail]
M. Battaglia Parodi, Dr. Department of Ophthalmology University Vita-Salute Scientific Institute San Raffaele Via Olgettina, 60 IT-20132 Milano (Italy) E-Mail [e-mail]
M. Bolz, Dr. Department of Ophthalmology and Optometry Medical University Vienna Waehringer Guertel 18-20 AT-1090 Vienna (Austria) E-Mail [e-mail]
A. Buchholz, Dr. Augenklinik Moltkestrasse 90 DE-76133 Karlsruhe (Germany) E-Mail [e-mail]
P. Buchholz, Dr. Augenklinik Moltkestrasse 90 DE-76133 Karlsruhe (Germany) E-Mail [e-mail]
W. Buehl, Dr. Department of Ophthalmology and Optometry Medical University Vienna Waehringer Guertel 18-20 AT-1090 Vienna (Austria) E-Mail [e-mail]
H. de Groot, Dr. Augenklinik Moltkestrasse 90 DE-76133 Karlsruhe (Germany) E-Mail [e-mail]
P. Iacono. Dr. Fondazione G.B. Bietti per l'Oftalmologia IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) Via Livenza 3 IT-00198 Rome (Italy) E-Mail [e-mail]
M.J. Jager, Prof. Department of Ophthalmology LUMC PO Box 9600 NL-2300 RC Leiden (The Netherlands) E-Mail [e-mail]
J. Kirchhof, Dr. Augenklinik Moltkestrasse 90 DE-76133 Karlsruhe (Germany) E-Mail [e-mail]
G.S. Missotten, Prof. Department Ophthalmology Academic Medical Center Meibergdreef 9 NL-1100DD Amsterdam (The Netherlands) E-Mail [e-mail]
C. Mitsch, Dr. Department of Ophthalmology and Optometry Medical University Vienna Waehringer Guertel 18-20 AT-1090 Vienna (Austria) E-Mail [e-mail]
A. Pollreisz, Dr. Department of Ophthalmology and Optometry Medical University Vienna Waehringer Guertel 18-20 AT-1090 Vienna (Austria) E-Mail [e-mail]
S. Sacu, Dr. Department of Ophthalmology and Optometry Medical University Vienna Waehringer Guertel 18-20 AT-1090 Vienna (Austria) E-Mail [e-mail]
R.O. Schlingemann, Prof. Medical Retina Unit and Ocular Angiogenesis Group Department of Ophthalmology Academic Medical Center University of Amsterdam, A2-122 NL-1100 DD Amsterdam (The Netherlands) E-Mail [e-mail]
U. Schmidt-Erfurth, Prof. Department of Ophthalmology and Optometry Medical University Vienna Waehringer Guertel 18-20 AT-1090 Vienna (Austria) E-Mail [e-mail]
V. Schmit-Eilenberger, Dr. Augenklinik Moltkestrasse 90 DE-76133 Karlsruhe (Germany) E-Mail [e-mail]
S. Scholl, Dr. Augenklinik Moltkestrasse 90 DE-76133 Karlsruhe (Germany) E-Mail [e-mail]
M.J. Siemerink, Dr. Medical Retina Unit and Ocular Angiogenesis Group Department of Ophthalmology Academic Medical Center University of Amsterdam, A2-122 NL-1100 DD Amsterdam (The Netherlands) E-Mail [e-mail]
F.D. Verbraak, Dr. Departments of Ophthalmology and Biomedical Engineering & Physics Academic Medical Center Meibergdreef 9 NL-1105 AZ Amsterdam (The Netherlands) E-Mail [e-mail]
 
Preface
The development of vascular endothelial growth factor inhibitors for the treatment of ocular neovascularization and macular edema can be regarded as the beginning of a new era in ophthalmological therapy. Before the year 2000, the treatment of any vascular abnormality in the macular region was merely restricted to conventional laser photocoagulation. Indubitably, laser treatment represents a destructive procedure which leads to a permanent scar and brings about a retinal sensitivity deterioration in all cases. Since 2000, photodynamic therapy with verteporfin has been introduced as the first attempt to couple laser energy with a light-sensitive drug in an attempt to treat choroidal neovascularization through a relatively non-